| Four Small Caps for Binary Event Investors Mike Havrilla submits:Below is a selection of companies with stock prices below $5 per share and upcoming binary events in the form of FDA news/decisions or clinical trial results that are expected within the next three months. A common strategy used by many investors is to buy a basket of several small or micro-cap companies (generally less than $1 billion market cap stocks) with pending binary events approximately 3-6 months ahead of the expected catalyst date, and sell into the expected upward momentum in both stock price and trading volume. Click here for a four-minute video that includes an overview of mikehavRx.com and this binary event investing strategy. Extreme trades such as those profiled below can be viewed as call option trades due to their low stock prices and high risk/reward profile. For this reason, investing in a basket of several low-priced stocks with pending binary events and following the strategy outlined above is an effective way to mitigate the risk of investment losses while participating in the potential run-up in stock price as the catalyst date approaches. Complete Story » seekingalpha.com |
DNA-Test Results Mislead Consumers, Says U.S. Genetic-testing companies that promised to help consumers understand their health risks instead offered contradictory and misleading results, government investigators said. online.wsj.com |
Cord Blood America Signs DNA Testing Deal; Offers Families Predetermination Testing Services (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today announced that within 90 days it will begin selling DNA Predisposition testing services in conjunction with The DNA Shop, LLC, , Henderson, Nevada. us.rd.yahoo.com |
Sanofi's Hostile Bid: Despite Problems, Genzyme Has Value Sanofi-Aventis (NYSE: SNY) said Monday that it has launched an $18.5 billion hostile offer for biotech company Genzyme (Nasdaq: GENZ), after it became fed-up with the Genzyme board's "unwillingness to engage" in discussions. The $69 per share offer is unchanged from the friendly proposal Sanofi-Aventis made privately to Genzyme's board of directors in July, which was promptly rejected publicly in August.Complete Story » seekingalpha.com |
GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloitte's 2010 Technology Fast 500 [PR Newswire] - GeneLink BioSciences, Inc. , a leading consumer genomics biotech company, today announced that it ranked number 62 on Technology Fast 500â„¢, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Â Rankings are based on percentage of fiscal year growth during the period from 2005-2009. Â GeneLink grew 2057 percent during this period. us.rd.yahoo.com |